Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clinical benefits from lowering cholesterol
Autore:
Maciejko, JJ;
Indirizzi:
St John Hosp & Med Ctr, Div Cardiol, Detroit, MI 48236 USA St John Hosp & Med Ctr Detroit MI USA 48236 ardiol, Detroit, MI 48236 USA
Titolo Testata:
JOURNAL OF CLINICAL LIGAND ASSAY
fascicolo: 1, volume: 24, anno: 2001,
pagine: 6 - 12
SICI:
1081-1672(200121)24:1<6:CBFLC>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY-ARTERY DISEASE; LOW-DENSITY-LIPOPROTEIN; ACUTE MYOCARDIAL-INFARCTION; HEART-DISEASE; REDUCTASE INHIBITORS; APOLIPOPROTEIN-B; PRIMARY PREVENTION; COLESTIPOL-NIACIN; RANDOMIZED TRIALS; BYPASS-SURGERY;
Keywords:
coronary heart disease; HMG CoA reductase inhibitors (statins); low density lipoprotein (LDL) cholesterol; plaque stabilization; atherosclerosis; National Cholesterol Education Program;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
65
Recensione:
Indirizzi per estratti:
Indirizzo: Maciejko, JJ St John Hosp & Med Ctr, Div Cardiol, 22151 Moross Rd,PBI Suite 105, Detroit, MI 48236 USA St John Hosp & Med Ctr 22151 Moross Rd,PBI Suite 105 Detroit MI USA 48236
Citazione:
J.J. Maciejko, "Clinical benefits from lowering cholesterol", J CLIN LIG, 24(1), 2001, pp. 6-12

Abstract

Since the publication of the National Cholesterol Education Program (NCEP)Adult Treatment Panel II (ATP II) guidelines in 1993, several large coronary heart disease (CHD) prevention trials using lipid-lowering medications have been published. These trials have involved the participation of tens-of-thousands of subjects, most with clinically evident CHD at baseline (secondary prevention) and some without (primary prevention). The results of these studies have beers consistent in showing that lowering serum low-density lipoprotein-cholesterol (LDL-C) concentrations reduces the incidence of coronary end-points (non-fatal myocardial infarction [MT], CHD death, and the need for coronary revascularization procedures). Furthermore, the extent ofthis clinical benefit appears to be proportional to the degree of LDL-C reduction. These trials found no evidence of adverse effects (e.g., increasedcancer incidence) even in the participants who achieved very low levels ofLDL-C (i,e., < 80 mg/dL), Based on the consistency of these results, it issuggested that the NCEP guidelines be modified in some of our highest riskpatients, including those with atherosclerotic cardiovascular disease and/or a diagnosis of diabetes mellitus, a suggested modification would be to either reduce the serum LDL-C concentration to 100 mg/dL, or 30% below the baseline level, whatever is greater, in these high risk patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 01:11:03